@prefix this: <http://purl.org/np/RAEhbEJ1tdhPqM6gNPScX9vIY1ZtUzOz7woeJNzB3sh3E> .
@prefix sub: <http://purl.org/np/RAEhbEJ1tdhPqM6gNPScX9vIY1ZtUzOz7woeJNzB3sh3E#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix pav: <http://purl.org/pav/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix infores: <https://w3id.org/biolink/infores/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix umls: <http://identifiers.org/umls/> .
@prefix orcid: <https://orcid.org/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubInfo ;
    a np:Nanopublication .
}
sub:assertion {
   <http://identifiers.org/pubchem.compound/492405> a biolink:ChemicalEntity ;
    rdfs:label "Favipiravir" ;
    biolink:category biolink:ChemicalEntity .
  umls:C1299487 a biolink:OrganismTaxon ;
    rdfs:label "patients" ;
    biolink:category biolink:OrganismTaxon .
  <http://purl.obolibrary.org/obo/MONDO_0005737> a biolink:DiseaseOrPhenotypicFeature , biolink:OrganismTaxon ;
    rdfs:label "Ebola" ;
    biolink:category biolink:DiseaseOrPhenotypicFeature , biolink:OrganismTaxon .
  <http://purl.obolibrary.org/obo/MONDO_0005812> a biolink:DiseaseOrPhenotypicFeature ;
    rdfs:label "influenza" ;
    biolink:category biolink:DiseaseOrPhenotypicFeature .
  sub:_1 rdf:object <http://purl.obolibrary.org/obo/MONDO_0005737> ;
    rdf:predicate biolink:treats ;
    rdf:subject <http://identifiers.org/pubchem.compound/492405> ;
    a biolink:Association ;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory ;
    biolink:category biolink:Association ;
    biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc5ddcf2-640c-4683-a60f-ca1c8b418873> .
  sub:_2 rdf:object <http://purl.obolibrary.org/obo/MONDO_0005812> ;
    rdf:predicate biolink:treats ;
    rdf:subject <http://identifiers.org/pubchem.compound/492405> ;
    a biolink:Association ;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory ;
    biolink:category biolink:Association ;
    biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc5ddcf2-640c-4683-a60f-ca1c8b418873> .
}
sub:provenance {
   sub:assertion prov:generatedAtTime "2022-10-13T13:56:25.822692"^^xsd:dateTime ;
    prov:wasAttributedTo orcid:0000-0002-3668-2627 ;
    prov:wasQuotedFrom " Favipiravir was approved in Japan in 2014 to treat cases of influenza that were unresponsive to conventional treatment. It has been investigated in other countries to treat novel viruses including Ebola and most recently, COVID-19, which was recently approved in the U.S. for treatment of novel viruses such as Ebola and the Ebola virus. Given its efficacy at targetting several strains of influenza, it has been used in Japan to treat influenza patients." .
  biolink: pav:version "2.3.0" .
}
sub:pubInfo {
   sub:sig npx:hasAlgorithm "RSA" ;
    npx:hasPublicKey "MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApdULbl+/+pkVlq0fAzWmzfgIb+XMuQPKHMDVzUTWCZBjLfzORll42ptr52e4w7tTYkUKrBsQbx8lkjZWAlWiyh+xIK0oLFSdYRSt63kgiyRYBUOR+spcgmofb7f6JyftArPVTKhsWOMt/mcyNG9qc3lw8B/xuPmLteUWO33xWhfXQreTw1lsGUkZ1j4cB4X9HIuI20ktLYLCXaBauNHEJZ4qp6/Q2ATsJcw8tg7aRmFKXhrjM9maZ2+0cMg0Jpmn2UnDlPKXEA6Qq+qnvvQt8KFjIzP9FTMyvrWl8tTd0NCmS9VpooZJQ8We1lGMPXg5bMbe/bVkTf70fbFMf0RKrQIDAQAB" ;
    npx:hasSignature "c0Xp6Q8x8xWOEMvfkEhnwmF+uZP/HEYkXnPJ4qW/pggf4VvxacMI/ef4XG5+eXcjxm9EtMfXalFTLqvIooVrx6tKLN1p2nnnhtNbGlk3PN+PxmTswsXfNM0c5q3g+63sCv6vet0yztsojlKJ4RfArR1ma/81B9iDU4RRrZwt2B8rHCVx1/yUnOsZmTmcfq/h5cEkszgXH+vh94rEJ1ywJwSMd/rCED/2UvzHrrjMD5Nfe5nlkTjM8u5gKNPlen/MkpMMDXxA52KD6nuVSRvzVCwM6FDKPy9PxsInDVcvCDfIrkupDk3Vs4WYl0VGYX91lqMW/X7oiPKOJGs4vQKR7w==" ;
    npx:hasSignatureTarget this: .
  this: prov:generatedAtTime "2022-10-13T13:56:25.822692"^^xsd:dateTime ;
    prov:wasAttributedTo orcid:0000-0002-3668-2627 .
}